M E Erwin - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

M E Erwin

Showing results (71-80 of 81) with videos related to

Pageof 9

Sort By:

Journal of Clinical Microbiology|May 1, 1992

MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacinM E Erwin, R N Jones, F P Koontz, et al.

Journal of Clinical Microbiology|March 1, 1992

Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycinM J Bale, R N Jones, M E Erwin, et al.

Journal of Clinical Microbiology|January 1, 1992

MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycinM J Bale, R N Jones, M E Erwin, et al.

Diagnostic Microbiology and Infectious Disease|August 1, 1993

In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centersH S Sader, R N Jones, J A Washington, et al.

Diagnostic Microbiology and Infectious Disease|November 22, 1997

Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study GroupR N Jones, S A Marshall, M A Pfaller, et al.

Journal of Clinical Microbiology|June 1, 1995

Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1G V Doern, R N Jones, E H Gerlach, et al.

Diagnostic Microbiology and Infectious Disease|September 1, 1991

Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelinesR N Jones, E H Gerlach, F P Koontz, et al.

Diagnostic Microbiology and Infectious Disease|August 1, 1992

Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelinesE H Gerlach, R N Jones, S D Allen, et al.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 1, 1991

Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolatesP R Murray, S D Allen, M E Erwin, et al.

Antimicrobial Agents and Chemotherapy|July 1, 1991

In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolatesJ A Washington, R N Jones, S D Allen, et al.

Pageof 9

Search research articles

Showing results (71-80 of 81) with videos related to

Sort By:

Pageof 9

Journal of Clinical Microbiology|May 1, 1992

Journal of Clinical Microbiology|March 1, 1992

Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycinM J Bale, R N Jones, M E Erwin, et al.

Journal of Clinical Microbiology|January 1, 1992

Diagnostic Microbiology and Infectious Disease|August 1, 1993

In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centersH S Sader, R N Jones, J A Washington, et al.

Diagnostic Microbiology and Infectious Disease|November 22, 1997

Journal of Clinical Microbiology|June 1, 1995

Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1G V Doern, R N Jones, E H Gerlach, et al.

Diagnostic Microbiology and Infectious Disease|September 1, 1991

Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelinesR N Jones, E H Gerlach, F P Koontz, et al.

Diagnostic Microbiology and Infectious Disease|August 1, 1992

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 1, 1991

Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolatesP R Murray, S D Allen, M E Erwin, et al.

Antimicrobial Agents and Chemotherapy|July 1, 1991

In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolatesJ A Washington, R N Jones, S D Allen, et al.

Pageof 9